ScreenPoint Medical Acquires Biomediq A S to Expand Breast Cancer Risk Assessment Capabilities

Research Published in Radiology Shows that Combination of Transpara-based Lesion Detection, Volumetric Density and Quantitative Texture Analysis Delivers Improved Breast Cancer Risk Prediction NIJMEGEN, The Netherlands, Jan. 8, 2025 /PRNewswire/

ScreenPoint Medical today announced the acquisition of Biomediq A/S, a research-based company focused on the research, development and implementation of quantitative imaging biomarkers. After a decade of close collaboration as separate entities on image based Risk Assessment, this deal is expected to bring Breast Cancer Risk Assessment Capabilities to ScreenPoint's industry-leading Breast AI, Transpara.The Breast Cancer Risk analysis technology from Biomediq enables automatic, computer-based analysis of 2D and 3D mammograms for analysis of future Risk of Breast Cancer.
ScreenPoint Medical Acquires Biomediq A S to Expand Breast Cancer Risk Assessment Capabilities

Liberoquotidiano.it - ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities

Leggi su Liberoquotidiano.it
  • ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
  • ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities - Research Published in Radiology Shows that Combination of Transpara-based Lesion Detection, Volumetric Density and Quantitative Texture Analysis Delivers Improved Breast Cancer Risk Prediction ... (adnkronos.com)
Video ScreenPoint Medical